nivolumab,ipilimumab
bms
['ipi/', 'lung', 'nivo', 'increase,(-increased)', 'medsir']
the #increase trial presented by dr. idris bahce - pcr achieved in 15/24 (63%) pts with resectable and borderline resectable lung cancer receiving ipi/nivo/crt. mpr rate: 79%, g3-4 trae: 56%. #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM